Contract Research and Manufacturing Orgs
Filter by Publisher
BioInformatics
IMV
Kalorama
SDI
The Market for Contract Manufacturing in IVD, 2022
September 2, 2022
The Market for Contract Manufacturing in In Vitro Diagnostics (IVD), 2022 provides valuable insights into the global in vitro diagnostic (IVD) industry’s contract manufacturing segment, covering market size, trends, and competitive analysis.
Report Highlights:
- Market Overview:
- Detailed examination of the multi-billion-dollar contract manufacturing segment within the IVD industry.
- Analysis of how leading…
$4,800.00 – $7,200.00$6,000.00 – $9,000.00
Market for Cell and Gene Therapy Contract Manufacturing Organizations (CMOs)
April 12, 2021
Contract manufacturing is becoming increasingly vital in the pharmaceutical industry, particularly in cell and gene therapy due to the high demand for these innovative products. Kalorama Information’s report, Market for Cell and Gene Therapy Contract Manufacturing Organizations (CMOs), provides comprehensive insights into this dynamic market.
Report Highlights:
- Biopharmaceutical Contract Manufacturing Market: In-depth analysis of…
$2,400.00 – $3,600.00$4,000.00 – $6,000.00
Outsourcing in Drug Discovery, 9th Edition
May 28, 2020
Outsourcing drug discovery represents the initial phase of the drug development process. By outsourcing segments of their drug discovery programs, pharmaceutical and biotechnology companies have discovered a cost-effective strategy that enhances hit-to-lead conversion and early identification of ineffective compounds. Outsourcing accelerates the drug discovery process, transforming the industry from low-end research services to high-value, sophisticated…
$2,750.00 – $4,125.00$5,500.00 – $8,250.00

2020 Contract Research Organization Market Opportunity Report
April 29, 2020
Contract research organizations (CROs) are essential partners in the drug development field. As companies in the pharmaceutical and biotechnology industries shift their development pipelines towards more targeted therapies, the cost of development has significantly increased while the patient pool for each drug is smaller. This has resulted in leaner R&D infrastructures and increasing reliance on…
$6,000.00
